Anti-Coagulant Research



Our development program centers around Tecarfarin, an oral anti-coagulant drug candidate with potential for treatment of patients with prosthetic heart valves. This drug candidate is in late-stage clinical trials and has received a Special Protocol Assessment (SPA) from the FDA.

Read More

Anti-Arrhythmic Research



Our development program also includes a focus on budiodarone, an oral anti-arrhythmic drug candidate being investigated for the prevention of life threatening ventricular tachycardia in patients with an implantable cardioverter defibrillator. Budiodarone demonstrated a dose-dependent reduction of atrial fibrillation burden in a Phase 2 study (PASCAL). Budiodarone is in Phase 2 development.

Read More